Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10046512HBVENSG00000184984.10protein_codingCHRM5NoNo1133P08912
Q8IVW0
TVIS30086165HIVENSG00000184984.10protein_codingCHRM5NoNo1133P08912
Q8IVW0
TVIS30037769HIVENSG00000184984.10protein_codingCHRM5NoNo1133P08912
Q8IVW0
TVIS20007173HPVENSG00000184984.10protein_codingCHRM5NoNo1133P08912
Q8IVW0
TVIS20007241HPVENSG00000184984.10protein_codingCHRM5NoNo1133P08912
Q8IVW0
TVIS20045839HPVENSG00000184984.10protein_codingCHRM5NoNo1133P08912
Q8IVW0
TVIS44041826HTLV-1ENSG00000184984.10protein_codingCHRM5NoNo1133P08912
Q8IVW0
TCGA Plot Options
Drug Information
GeneCHRM5
DrugBank IDDB00496
Drug NameDarifenacin
Target IDBE0000247
UniProt IDP08912
Regulation Typeantagonist
PubMed IDs10374898; 18046909
CitationsMoriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.@@Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16.
GroupsApproved; Investigational
Direct ClassificationDiphenylmethanes
SMILESNC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Pathways
PharmGKBPA164774901
ChEMBLCHEMBL1346